BOSTON -- Investigational crinecerfont reduced the need for glucocorticoids in adults and kids with congenital adrenal hyperplasia (CAH), two phase III trials found. In the adult trial of 182 patients ...
Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...
SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders ...
Please provide your email address to receive an email when new articles are posted on . Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal ...
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
Congenital adrenal hyperplasia (CAH) represents a group of inherited disorders resulting from enzyme deficiencies that disrupt the synthesis of adrenal steroid hormones. One notable form, caused by ...
Steroid biosynthesis is affected in the AR disorder known as congenital adrenal hyperplasia (CAH): the majority of cases are due to 21-hydroxylase deficiency. Androgen excess affects women’s ...
(BPT) – This article was sponsored and developed by Neurocrine Biosciences, Inc. Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition involving the adrenal glands that is ...
Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical congenital ...
"Congenital Adrenal Hyperplasia Treatment Market"Congenital adrenal hyperplasia companies are Crinetics Pharmaceuticals, Diurnal Limited, Adrenas Therapeutics, Neurocrine Biosciences, Lundbeck, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback